Information  X 
Enter a valid email address

Shield Therapeutics (STX)

  Print   

Wednesday 11 August, 2021

Shield Therapeutics

Notice of Results

RNS Number : 2111I
Shield Therapeutics PLC
11 August 2021
 

 

Shield Therapeutics plc

("Shield or the "Company" or the "Group")

 

Notice of Results

 

London, UK, 11 August 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), will announce its interim results for the six months ended 30 June 2021 on Tuesday 17 August 2021.

 

Analyst briefing

A briefing open to analysts will take place remotely via video conference call on Tuesday 17 August 2021 at 14.00 (BST). If you would like the details of this call please contact Walbrook PR on  [email protected] .

 

 

For further information, please contact:

 

Shield Therapeutics plc

+44 (0) 191 511 8500

Greg Madison (CEO)

Hans-Peter Rudolf (CFO)

 

 

 

Peel Hunt LLP - Nominated Adviser & Joint Broker

  +44 (0) 20 7148 8900

James Steel / Christopher Golden

 

 

 

finnCap Ltd - Joint Broker

  +44 (0) 20 7220 0500

Geoff Nash / Alice Lane/ George Dollemore  

 

 

 

Walbrook PR - Financial PR & IR Adviser

+44 (0) 20 7933 8780

Paul McManus / Lianne Cawthorne/ Alice Woodings

or [email protected]

       

 

 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

 

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer® in the US. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORBLGDIDGBDGBG

a d v e r t i s e m e n t